Swiss National Bank Karuna Therapeutics, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$161.01 - $317.85 $1.11 Million - $2.19 Million	-6,900 Reduced 9.86%	63,100 $20 Million
Q3 2023 Nov 08, 2023	BUY	$164.66 - $218.08 $806,834 - $1.07 Million	4,900 Added 7.53%	70,000 $11.8 Million
Q2 2023 Aug 09, 2023	BUY	$176.32 - $240.22 $1.01 Million - $1.37 Million	5,700 Added 9.6%	65,100 $14.1 Million
Q1 2023 May 10, 2023	SELL	$161.33 - $204.36 $838,916 - $1.06 Million	-5,200 Reduced 8.05%	59,400 $10.8 Million
Q4 2022 Feb 08, 2023	BUY	$191.53 - $236.82 $248,989 - $307,866	1,300 Added 2.05%	64,600 $12.7 Million
Q3 2022 Nov 09, 2022	BUY	$123.79 - $277.42 $1.32 Million - $2.97 Million	10,700 Added 20.34%	63,300 $14.2 Million
Q2 2022 Aug 09, 2022	BUY	$93.97 - $143.33 $328,895 - $501,655	3,500 Added 7.13%	52,600 $6.65 Million
Q1 2022 May 09, 2022	BUY	$98.9 - $132.37 $365,930 - $489,769	3,700 Added 8.15%	49,100 $6.23 Million
Q4 2021 Feb 08, 2022	SELL	$110.64 - $159.4 $11,064 - $15,940	-100 Reduced 0.22%	45,400 $5.95 Million
Q3 2021 Nov 08, 2021	BUY	$101.2 - $125.87 $384,560 - $478,306	3,800 Added 9.11%	45,500 $5.57 Million
Q2 2021 Aug 06, 2021	BUY	$107.45 - $135.95 $1.52 Million - $1.92 Million	14,100 Added 51.09%	41,700 $4.75 Million
Q1 2021 May 07, 2021	BUY	$95.46 - $133.08 $47,730 - $66,540	500 Added 1.85%	27,600 $3.32 Million
Q4 2020 Feb 05, 2021	BUY	$75.23 - $109.23 $30,092 - $43,692	400 Added 1.5%	27,100 $2.75 Million
Q3 2020 Nov 09, 2020	BUY	$71.31 - $109.74 $35,655 - $54,870	500 Added 1.91%	26,700 $2.06 Million
Q2 2020 Aug 05, 2020	BUY	$62.14 - $117.21 $1.63 Million - $3.07 Million	26,200 New	26,200 $2.92 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account